Reuters-Health
Date: Thu, 6 Nov 2025 13:56:30 -0500 (EST)
Subject: Common antibiotic may reduce schizophrenia risk
(Converted from HTML)
Plus, Melatonin linked to heart failure.
Get full access to Reuters.com for just $1/week. Subscribe now.
?
Health Rounds
Health Rounds
By Kate Turton
Hello, I am in for Nancy today. I won't go in-depth on the latest medical research as she does, but two recent studies caught my eye: Research has shown a common antibiotic may cut schizophrenia risk, and melatonin use for sleep might have heart health implications. More in the newsletter below.
But first, see these breaking news stories from our Reuters team: US to announce new dietary guidelines in December, Kennedy says; US FDA expands use of J&J's Caplyta as add-on depression drug; Novo Nordisk CEO faces baptism of fire amid board shakeup, Pfizer fight; and what is Metsera , the target in Pfizer's and Novo Nordisk's bidding war?
Also: US FDA cleared pricey rare disease drug over reviewer objections; scientists unveil first draft of atlas of the developing brain ; Canada to cull ostrich herd infected with bird flu after top court declines to hear farm's case; and Texas seeks to block Kenvue dividend amid Tylenol lawsuit;
?
Industry Updates
AstraZeneca holds forecasts as cancer, heart drugs lift earnings
Lilly moves obesity drug to late-stage trials after it shows promise
Nordic Capital, Permira takeover offer for Bavarian Nordic falls through
Novavax defers profitability target by a year on weak COVID vaccine sales
BillionToOne valued at $4.4 billion as shares surge in blockbuster Nasdaq debut
Bristol Myers reaches $239 million settlement over psoriasis, MS drugs
Microsoft launches 'superintelligence' team targeting medical diagnosis to start
Novo Nordisk expects global sales to decline by low single digits in 2026
Biovac opens new vaccine lab in Cape Town to boost Africa's manufacturing capacity
?
?
Novo Nordisk, Lilly strike pricing deal with Trump for weight-loss drugs
Donald Trump, in front of Novo Nordisk CEO Maziar Mike Doustdar and Eli Lilly CEO David A. Ricks at the White House in Washington, D.C. November 6, 2025. REUTERS/Jonathan Ernst
U.S. President Donald Trump, Eli Lilly and Novo Nordisk unveiled a deal to slash the prices of popular GLP-1 weight*loss drugs for the government's Medicare and Medicaid programs, as well as for cash payers.
The move is aimed at increasing access to the treatments through U.S. Medicare for people aged 65 and over and the Medicaid program for low-income people, which together provide healthcare coverage for nearly half of all Americans.
?
Study Rounds
Two studies: antibiotic's possible upside, melatonin's potential heart risk
?
A commonly prescribed antibiotic could help reduce the risk of some young people developing schizophrenia, new research from the University of Edinburgh suggests.
The large population-based study, which analyzed data from more than 56,000 young patients, found that doxycycline may reduce the risk of schizophrenia. Researchers found that those who took the common antibiotic had a 30%–35% lower chance of developing schizophrenia later in life.
They hypothesize the effect arises from doxycycline’s ability to calm brain inflammation.
As an observational study, rather than a randomized clinical trial, however, their findings cannot prove that doxycycline caused the risk reduction.
The other study making waves this week is about potential drawbacks of melatonin use for sleep regulation. Research from an unpublished study to be presented at the American Heart Association scientific meeting in New Orleans next week claims to have linked melatonin supplements to a 90% increase in the risk of heart failure.
The study, which has not been peer reviewed, saw researchers analyze health records from more than 130,000 adults with insomnia, divided into groups of people who took melatonin supplements for at least one year, and those who had no record of melatonin use.
The risk of developing heart failure was 4.6% for those who took melatonin, while those who never used the supplement had a risk of 2.7%, they found. Heart failure is a chronic condition in which the heart becomes too weak to sufficiently pump blood throughout the body.
The study had several drawbacks, including only counting people with documented melatonin prescriptions, and lacking information about the severity of subjects' insomnia, which can cause other health problems.
?
In case you missed it...
Health Rounds: Sound waves promote healing of diabetic foot ulcers
Health Rounds: Viruses may hold key to tackling deadly bacterial infection
?
This newsletter was edited by Bill Berkrot
?
Sponsors are not involved in the creation of newsletters or other Reuters news content. Advertise in this newsletter or on Reuters' website
?
Reuters Health Rounds is sent twice a week. Think your friend or colleague should know about us? Forward this newsletter to them. They can also sign up here .
Want to stop receiving this email? Unsubscribe here . To manage which newsletters you're signed up for, click here .
This email includes limited tracking for Reuters to understand whether you’ve engaged with its contents. For more information on how we process your personal information and your rights, please see our Privacy Statement .
Terms & Conditions
?
© 2025 Thomson Reuters. All rights reserved.
3 Times Square, New York, NY 10036
Subject: Common antibiotic may reduce schizophrenia risk
(Converted from HTML)
Plus, Melatonin linked to heart failure.
Get full access to Reuters.com for just $1/week. Subscribe now.
?
Health Rounds
Health Rounds
By Kate Turton
Hello, I am in for Nancy today. I won't go in-depth on the latest medical research as she does, but two recent studies caught my eye: Research has shown a common antibiotic may cut schizophrenia risk, and melatonin use for sleep might have heart health implications. More in the newsletter below.
But first, see these breaking news stories from our Reuters team: US to announce new dietary guidelines in December, Kennedy says; US FDA expands use of J&J's Caplyta as add-on depression drug; Novo Nordisk CEO faces baptism of fire amid board shakeup, Pfizer fight; and what is Metsera , the target in Pfizer's and Novo Nordisk's bidding war?
Also: US FDA cleared pricey rare disease drug over reviewer objections; scientists unveil first draft of atlas of the developing brain ; Canada to cull ostrich herd infected with bird flu after top court declines to hear farm's case; and Texas seeks to block Kenvue dividend amid Tylenol lawsuit;
?
Industry Updates
AstraZeneca holds forecasts as cancer, heart drugs lift earnings
Lilly moves obesity drug to late-stage trials after it shows promise
Nordic Capital, Permira takeover offer for Bavarian Nordic falls through
Novavax defers profitability target by a year on weak COVID vaccine sales
BillionToOne valued at $4.4 billion as shares surge in blockbuster Nasdaq debut
Bristol Myers reaches $239 million settlement over psoriasis, MS drugs
Microsoft launches 'superintelligence' team targeting medical diagnosis to start
Novo Nordisk expects global sales to decline by low single digits in 2026
Biovac opens new vaccine lab in Cape Town to boost Africa's manufacturing capacity
?
?
Novo Nordisk, Lilly strike pricing deal with Trump for weight-loss drugs
Donald Trump, in front of Novo Nordisk CEO Maziar Mike Doustdar and Eli Lilly CEO David A. Ricks at the White House in Washington, D.C. November 6, 2025. REUTERS/Jonathan Ernst
U.S. President Donald Trump, Eli Lilly and Novo Nordisk unveiled a deal to slash the prices of popular GLP-1 weight*loss drugs for the government's Medicare and Medicaid programs, as well as for cash payers.
The move is aimed at increasing access to the treatments through U.S. Medicare for people aged 65 and over and the Medicaid program for low-income people, which together provide healthcare coverage for nearly half of all Americans.
?
Study Rounds
Two studies: antibiotic's possible upside, melatonin's potential heart risk
?
A commonly prescribed antibiotic could help reduce the risk of some young people developing schizophrenia, new research from the University of Edinburgh suggests.
The large population-based study, which analyzed data from more than 56,000 young patients, found that doxycycline may reduce the risk of schizophrenia. Researchers found that those who took the common antibiotic had a 30%–35% lower chance of developing schizophrenia later in life.
They hypothesize the effect arises from doxycycline’s ability to calm brain inflammation.
As an observational study, rather than a randomized clinical trial, however, their findings cannot prove that doxycycline caused the risk reduction.
The other study making waves this week is about potential drawbacks of melatonin use for sleep regulation. Research from an unpublished study to be presented at the American Heart Association scientific meeting in New Orleans next week claims to have linked melatonin supplements to a 90% increase in the risk of heart failure.
The study, which has not been peer reviewed, saw researchers analyze health records from more than 130,000 adults with insomnia, divided into groups of people who took melatonin supplements for at least one year, and those who had no record of melatonin use.
The risk of developing heart failure was 4.6% for those who took melatonin, while those who never used the supplement had a risk of 2.7%, they found. Heart failure is a chronic condition in which the heart becomes too weak to sufficiently pump blood throughout the body.
The study had several drawbacks, including only counting people with documented melatonin prescriptions, and lacking information about the severity of subjects' insomnia, which can cause other health problems.
?
In case you missed it...
Health Rounds: Sound waves promote healing of diabetic foot ulcers
Health Rounds: Viruses may hold key to tackling deadly bacterial infection
?
This newsletter was edited by Bill Berkrot
?
Sponsors are not involved in the creation of newsletters or other Reuters news content. Advertise in this newsletter or on Reuters' website
?
Reuters Health Rounds is sent twice a week. Think your friend or colleague should know about us? Forward this newsletter to them. They can also sign up here .
Want to stop receiving this email? Unsubscribe here . To manage which newsletters you're signed up for, click here .
This email includes limited tracking for Reuters to understand whether you’ve engaged with its contents. For more information on how we process your personal information and your rights, please see our Privacy Statement .
Terms & Conditions
?
© 2025 Thomson Reuters. All rights reserved.
3 Times Square, New York, NY 10036